Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis

This case report discusses a 64-year-old female patient who developed alopecia areata (AA) after starting secukinumab, an IL-17A inhibitor, for her plaque psoriasis. The report suggests a potential link between IL-17A inhibitors and the onset of AA, highlighting a rare but significant side effect. This is one of only three case reports that specifically address the association between IL-17A inhibitors and AA, indicating the need for further investigation into this potential side effect.